|
Feb 14
|
Alphamab doses first subject in trial of JSKN003 for ovarian cancer
|
|
Feb 13
|
High Growth Tech Stocks To Watch In February 2025
|
|
Feb 13
|
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
|
|
Dec 30
|
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer
|
|
Oct 17
|
IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved
|
|
Dec 4
|
First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer
|